Gene Expression Modulation by Small-molecules (GEMS(TM)) is PTC's novel and proprietary technology platform for the identification of small-molecules that modulate post-transcriptional control mechanisms. Compounds identified through the GEMS technology target processes that act through the untranslated regions (UTRs) of messenger RNA (mRNA) molecules. PTC has successfully employed the GEMS technology in drug discovery programs in oncology, infectious diseases, cardiovascular diseases, and neuromuscular disorders with corporate partners such as Celgene, Gilead, Pfizer, and Schering-Plough.
About Hepatitis C (HCV)
Hepatitis C is inflammation of the liver caused by the hepatitis C virus. Approximately 4 million people in the U.S. are infected with hepatitis C, according to the National Institutes of Health. Additionally, the World Health Organization estimates 170 million persons are chronically infected with HCV worldwide and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. At least 80% of patients with hepatitis C develop a chronic liver infection. It is the leading cause of liver failure requiring liver transplantation in both the United States and Europe. The Centers for Disease Control, or CDC, estimate that approximately 8,000 to 10,000 patients die annually in the United States from complications resulting from this infection. There are no available vaccines against HCV. The current standard of care for the treatment of HCV is a combination of two drugs, interferon and ribavirin. More than 50% of patients infected with the genotype 1 strain of HCV generally do not respond to this therapy. In addition, there are significant side effects to this therapy, which often result in dose reductions or prem
|SOURCE PTC Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved